Atumelnant + Placebo
Phase 2/3Recruiting 0 watching 0 views this week📈 Rising
60
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Congenital Adrenal Hyperplasia
Conditions
Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
Trial Timeline
Jan 22, 2026 → Mar 1, 2030
NCT ID
NCT07159841About Atumelnant + Placebo
Atumelnant + Placebo is a phase 2/3 stage product being developed by Crinetics Pharmaceuticals for Congenital Adrenal Hyperplasia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07159841. Target conditions include Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia.
Hype Score Breakdown
Clinical
22
Activity
15
Company
5
Novelty
7
Community
8
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07159841 | Phase 2/3 | Recruiting |
| NCT07144163 | Phase 3 | Recruiting |
| NCT07221084 | Phase 1 | Completed |
Competing Products
20 competing products in Congenital Adrenal Hyperplasia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tideglusib | AMO Pharma | Pre-clinical | 15 |
| Tideglusib + Placebo | AMO Pharma | Phase 2/3 | 57 |
| Tideglusib | AMO Pharma | Phase 2/3 | 57 |
| EDIT-101 | Editas Medicine | Phase 1/2 | 33 |
| Tildacerfont/Placebo | Spruce Biosciences | Phase 2 | 44 |
| SPR001 | Spruce Biosciences | Phase 2 | 44 |
| SPR001 | Spruce Biosciences | Phase 2 | 44 |
| Tildacerfont/Placebo | Spruce Biosciences | Phase 2 | 44 |
| Tildacerfont | Spruce Biosciences | Phase 2 | 44 |
| KW-3357 | Kyowa Kirin | Phase 1 | 33 |
| Pasireotide 0.6Mg Solution for Injection + Saline Solution | Novartis | Phase 2 | 52 |
| Sandostatine LP | Novartis | Phase 2 | 52 |
| mycophenolate mofetil | Roche | Phase 1 | 33 |
| turoctocog alfa + turoctocog alfa | Novo Nordisk | Phase 3 | 76 |
| catridecacog + recombinant factor XIII | Novo Nordisk | Phase 1 | 32 |
| activated recombinant human factor VII | Novo Nordisk | Phase 2 | 51 |
| turoctocog alfa pegol | Novo Nordisk | Phase 3 | 76 |
| recombinant factor XIII | Novo Nordisk | Pre-clinical | 22 |
| activated recombinant human factor VII, long acting + activated recombinant human factor VII, long acting | Novo Nordisk | Phase 1 | 32 |
| Advate® + turoctocog alfa | Novo Nordisk | Phase 1 | 32 |